The inflammasome is a protein complex composed of an intracellular sensor-typically a Nod-like receptor (NLR), the precursor procaspase-1, and the adaptor ASC. Inflammasome activation leads to the maturation of caspase-1 and the processing of its substrates, IL-1ß and IL-18. The inflammasome has been implicated numerous diseases, and blockade of inflammasome-derived IL-1ß has beneficial effects on several of these diseases. Different books have been edited about the biology of inflammasomes and about methods to study, however, the implication of this complex in the different diseases and pathological conditions show the need of a book about the clinical implications and therapeutic options. This project will show the context where inflammasomes are being studied and the molecular implications in the medical and clinical contexts. Other important topic of the inflammasomes will be the development of pharmacological inhibitors in order to improve new clinical applications. In this sense, we can find new drugs with inhibitory effects or old drugs with an inhibitory potential effect. There is a need for re-establishing the real benefits of the inflammasome inhibitions in pathological situations and the management of the differents diseases where inflammasomes are implicated.
AMPK has emerged as an important integrator of signals that control energy balance through the regulation of multiple biochemical pathways in eukaryotes. This book focuses on the implications of AMPK as a master metabolic regulator in diseases, including new methods and animal models. The contributions are written by leading experts in the field and give an extensive overview of the current knowledge of AMPK biology and the role of AMPK in health and disease.